{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=105&state=Michigan",
    "query": {
      "state": "Michigan",
      "city": "Detroit",
      "page": 105
    },
    "page_size": 10
  },
  "pagination": {
    "page": 105,
    "page_size": 10,
    "total_count": 7251,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=106&state=Michigan&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=104&state=Michigan&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T17:27:11.366Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07217587",
      "title": "Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Nipocalimab",
          "type": "DRUG"
        },
        {
          "name": "Efgartigimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 115,
      "start_date": "2026-01-05",
      "completion_date": "2029-01-29",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 20,
      "location_summary": "Fullerton, California • Pomona, California • Colorado Springs, Colorado + 17 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07217587"
    },
    {
      "nct_id": "NCT07222306",
      "title": "Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PTSD",
        "Suicidal Thoughts and Behaviors",
        "PTSD Symptoms",
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "1-(2-[+F]fluoroethyl)-L-tryptophan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wayne State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "19 Years to 69 Years"
      },
      "enrollment_count": 100,
      "start_date": "2026-01-01",
      "completion_date": "2030-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222306"
    },
    {
      "nct_id": "NCT01208233",
      "title": "Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "PF-03049423",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 181,
      "start_date": "2010-12",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-19",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Deerfield Beach, Florida • Fort Lauderdale, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01208233"
    },
    {
      "nct_id": "NCT02065687",
      "title": "Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IIIA Uterine Corpus Cancer AJCC v7",
        "Stage IIIB Uterine Corpus Cancer AJCC v7",
        "Stage IIIC Uterine Corpus Cancer AJCC v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Stage IVA Uterine Corpus Cancer AJCC v7",
        "Stage IVB Uterine Corpus Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Metformin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 469,
      "start_date": "2014-03-17",
      "completion_date": "2023-09-13",
      "has_results": true,
      "last_update_posted_date": "2021-09-30",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 431,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065687"
    },
    {
      "nct_id": "NCT04462406",
      "title": "Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Melanoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Melanoma of Unknown Primary",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Unresectable Acral Lentiginous Melanoma",
        "Unresectable Melanoma",
        "Unresectable Mucosal Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2021-02-09",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 482,
      "location_summary": "Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04462406"
    },
    {
      "nct_id": "NCT04031885",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2019-08-14",
      "completion_date": "2020-08-11",
      "has_results": true,
      "last_update_posted_date": "2021-08-24",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 55,
      "location_summary": "Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04031885"
    },
    {
      "nct_id": "NCT06685835",
      "title": "A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Brensocatib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 214,
      "start_date": "2024-12-16",
      "completion_date": "2026-06-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Coral Gables, Florida + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Margate",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06685835"
    },
    {
      "nct_id": "NCT02378961",
      "title": "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "VOX",
          "type": "DRUG"
        },
        {
          "name": "SOF/VEL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2015-02-16",
      "completion_date": "2016-01-26",
      "has_results": true,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 31,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378961"
    },
    {
      "nct_id": "NCT00004927",
      "title": "BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "R-Pharm",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": "2002-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • New York, New York",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004927"
    },
    {
      "nct_id": "NCT00004073",
      "title": "Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "suramin",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "1999-12",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2012-05-03",
      "last_synced_at": "2026-11-22T17:27:11.366Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004073"
    }
  ]
}